Topamax and Prohance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Topamax (topiramate) and Prohance (gadoteridol). Common drug interactions include deformity among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Topamax and Prohance. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Topamax?

Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 58,954 Topamax users. Check the latest studies of Topamax.

What is Prohance?

Prohance has active ingredients of gadoteridol. eHealthMe is studying from 3,734 Prohance users. Check the latest studies of Prohance.

On Jul, 17, 2026

24 people who take Topamax and Prohance together, and have interactions are studied.

What are the common drug interactions of Topamax and Prohance, by gender? *:

female:

Deformity (disfigurement)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Hyperkeratosis (thickening of the outer layer of the skin)
Joint range of motion decreased (disease of joint movement)
Joint stiffness
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema (fluid collection in tissue)
Oedema peripheral (superficial swelling)

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Cardiac arrest
Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
Skin tightness
Subcutaneous nodule
Xerosis (abnormal dryness of the skin or mucus membranes)
Endocardial fibrosis (cardiac fibrosis refers to an abnormal thickening of the heart valves)
Joint contracture (a permanent shortening of a muscle or joint)
Skin fibrosis (fibrous tissue formation on skin)
Discomfort

What are the common drug interactions of Topamax and Prohance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Cardiac arrest
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Metaplasia (change in the type of adult cells in a tissue to a form abnormal for that tissue)
Mobility decreased (ability to move is reduced)
Muscle contracture (a permanent shortening of a muscle)
Myocardial fibrosis (a condition in which the heart's muscle cells are impaired)
Pain in extremity
Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
Skin induration (an abnormally hard spot or area on the skin)

20-29:

n/a

30-39:

Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Deformity (disfigurement)
Hyperkeratosis (thickening of the outer layer of the skin)
Joint stiffness
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Rash
Skin discolouration (change of skin colour)
Joint contracture (a permanent shortening of a muscle or joint)

40-49:

Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
Chest pain
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Catheter Related Complication: 8 people, 33.33%
Joint Pain: 8 people, 33.33%
Pain: 6 people, 25.00%
Nuclear Magnetic Resonance Imaging Abdominal: 6 people, 25.00%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 20.83%
Weight Increased: 4 people, 16.67%
Dry Skin: 4 people, 16.67%
Conductive Deafness (deafness due to a problem in conducting sound waves): 4 people, 16.67%
Dizziness: 4 people, 16.67%
Dry Eyes (lack of adequate tears): 4 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Topamax and Prohance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously